Shares of clinical-stage biopharmaceutical company Zymeworks (NYSE:ZYME) are trending upward in the pre-market session today after the company entered into an exclusive licensing agreement with Jazz Pharmaceuticals (NASDAQ:JAZZ) for the development of Zanidatamab.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
While Jazz gains exclusive rights for the drug in key markets, Zymeworks gets an upfront payment of $50 million, a second payment of $325 million (optional to Jazz), and potential milestone payments of up to $1.76 billion (apart from royalties on sales).
Moreover, top-line data for the drug in biliary tract cancer is anticipated by the end of this year.
Read full Disclosure